UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 159

Sortiert nach

Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with Diabetes

The American journal of medicine, 2017-05, Vol.130 (5), p.614-614

2017

Volltextzugriff (PDF)

Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial

Diabetes care, 2010-03, Vol.33 (3), p.605-607

2010

Volltextzugriff (PDF)

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2413-2421

2019

Volltextzugriff (PDF)

Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 2 Diabetes

Diabetes care, 2008-09, Vol.31 (9), p.1723-1728

2008

Volltextzugriff (PDF)

220-OR: Characteristics Associated with Adding Insulin in Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes (GRADE) Study

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2022-01, Vol.327 (2), p.138

2022

Volltextzugriff (PDF)

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes results of a 6-month, randomized, comparative trial

Diabetes care, 2004-10, Vol.27 (10), p.2356-2362

2004

Volltextzugriff (PDF)

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes : A 1-year randomized controlled trial

Diabetes care, 2003-03, Vol.26 (3), p.784-790

2003

Volltextzugriff (PDF)

Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open‐label clinical trial

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2220-2228

2018

Volltextzugriff (PDF)

Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open‐label clinical trial

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2229-2237

2018

Volltextzugriff (PDF)

Once-Weekly Semaglutide in Adults with Overweight or Obesity

The New England journal of medicine, 2021-03, Vol.384 (11), p.989-1002

2021

Volltextzugriff (PDF)

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2021-04, Vol.325 (14), p.1414

2021

Volltextzugriff (PDF)

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

The New England journal of medicine, 2017-08, Vol.377 (7), p.644-657

2017

Volltextzugriff (PDF)

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Diabetes therapy, 2018-04, Vol.9 (2), p.827-837

2018

Volltextzugriff (PDF)

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

International Journal of Obesity, 2013-11, Vol.37 (11), p.1443-1451

2013

Volltextzugriff (PDF)

Insulin detemir for the treatment of obese patients with type 2 diabetes

Diabetes, metabolic syndrome and obesity, 2012-01, Vol.5 (default), p.11-19

Hollander, Priscilla A

2012

Volltextzugriff (PDF)

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2015-08, Vol.314 (7), p.687

2015

Volltextzugriff (PDF)

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

Diabetes care, 1998-08, Vol.21 (8), p.1288

1998

Volltextzugriff (PDF)

Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

Diabetes care, 2013-12, Vol.36 (12), p.4022-4029

2013

Volltextzugriff (PDF)

Efficacy and Safety of CP-945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance

Obesity (Silver Spring, Md.), 2011-07, Vol.19 (7), p.1404-1414

2011

Volltextzugriff (PDF)

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Diabetes care, 2018-09, Vol.41 (9), p.1938-1946

2018

Volltextzugriff (PDF)

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2010-08, Vol.376 (9741), p.595-605

2010

Volltextzugriff (PDF)

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet (British edition), 2012-04, Vol.379 (9825), p.1498-1507

2012

Volltextzugriff (PDF)

Body Weight Changes Associated With Insulin Therapy: A retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled Phase III trials

Diabetes care, 2007-10, Vol.30 (10), p.2508-2510

2007

Volltextzugriff (PDF)

Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial

Diabetes technology & therapeutics, 2009-11, Vol.11 (11), p.697

2009

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(140)
Mit Volltextzugriff
(137)

Publikationsform

Sprache

Englisch
(159)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(98)
Science & Technology
(98)
Humans
(95)
Female
(72)
Male
(69)
Endocrinology & Metabolism
(67)
Middle Aged
(64)
Diabetes
(63)
Adult
(51)
Diabetes Mellitus, Type 2 - Drug Therapy
(50)
Aged
(45)
Insulin
(36)
Treatment Outcome
(32)
Biological And Medical Sciences
(30)
Double-Blind Method
(30)
Medical Sciences
(30)
Diabetes Mellitus, Type 2 - Blood
(29)
Hypoglycemic Agents - Administration & Dosage
(29)
Hypoglycemic Agents - Therapeutic Use
(28)
Blood Glucose - Metabolism
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Where Are We Now? A Clinicians' Guide to the Use of Follow-On Insulin for Patients with Diabetes

Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100

Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 2 Diabetes

220-OR: Characteristics Associated with Adding Insulin in Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes (GRADE) Study

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial

Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes results of a 6-month, randomized, comparative trial

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes : A 1-year randomized controlled trial

Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open‐label clinical trial

Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open‐label clinical trial

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Similar Efficacy and Safety of Basaglar® and Lantus® in Patients with Type 2 Diabetes in Age Groups (< 65 Years, ≥ 65 Years): A Post Hoc Analysis from the ELEMENT-2 Study

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

Insulin detemir for the treatment of obese patients with type 2 diabetes

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

Efficacy and Safety of CP-945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Body Weight Changes Associated With Insulin Therapy: A retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled Phase III trials

Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial

Suchergebnisse filtern